Page last updated: 2024-10-24

plasma lipoprotein particle oxidation

Definition

Target type: biologicalprocess

The modification of a lipid or protein within a plasma lipoprotein particle by oxidation of the lipid or one or more amino acids. [GOC:BHF, GOC:mah]

Plasma lipoprotein particle oxidation is a complex process that plays a critical role in the development of atherosclerosis and cardiovascular disease. It involves the modification of lipoproteins, primarily low-density lipoproteins (LDLs), by reactive oxygen species (ROS). ROS, including free radicals like superoxide anions (O2-), hydroxyl radicals (OH-), and hydrogen peroxide (H2O2), can be generated from various sources, including inflammation, environmental pollutants, and metabolic processes.

When LDL particles encounter ROS, they undergo oxidation, leading to structural changes in their lipid and protein components. Oxidation of LDLs leads to the formation of oxidized LDL (oxLDL), which has several adverse effects:

1. Increased uptake by macrophages: oxLDL is readily taken up by macrophages in the arterial wall via scavenger receptors. This leads to the formation of foam cells, which are cholesterol-laden macrophages that contribute to plaque formation.

2. Inflammation: oxLDL activates inflammatory pathways, leading to the recruitment of inflammatory cells, such as monocytes and T cells, to the arterial wall. These cells further contribute to plaque development and instability.

3. Endothelial dysfunction: oxLDL can damage endothelial cells, the lining of blood vessels, leading to impaired vasodilation and increased permeability. This can facilitate the accumulation of inflammatory cells and lipids in the arterial wall.

4. Thrombosis: oxLDL can promote platelet aggregation and coagulation, increasing the risk of thrombus formation, which can lead to heart attack or stroke.

The oxidation process of LDL particles involves several steps:

1. Initiation: The process is initiated by the interaction of LDL with ROS, leading to the formation of lipid peroxyl radicals.

2. Propagation: Lipid peroxyl radicals react with other lipids in the LDL particle, leading to a chain reaction of oxidation.

3. Termination: The chain reaction is eventually terminated by the reaction of lipid peroxyl radicals with antioxidants or by the formation of stable oxidation products.

Factors that contribute to LDL oxidation include:

1. Increased ROS production: Conditions such as inflammation, smoking, diabetes, and hypertension can increase ROS production, leading to increased LDL oxidation.

2. Decreased antioxidant levels: Low levels of antioxidants, such as vitamin E, can increase susceptibility to LDL oxidation.

3. Genetic factors: Some individuals have genetic variations that make them more susceptible to LDL oxidation.

4. Lifestyle factors: A high-fat diet, lack of exercise, and stress can contribute to LDL oxidation.

In summary, plasma lipoprotein particle oxidation is a complex process that involves the modification of LDL particles by ROS. This process leads to the formation of oxLDL, which has several adverse effects on the cardiovascular system, ultimately contributing to the development of atherosclerosis and cardiovascular disease.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Platelet-activating factor acetylhydrolaseA platelet-activating factor acetylhydrolase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q13093]Homo sapiens (human)

Compounds (18)

CompoundDefinitionClassesRoles
ly 171883LY 171883: structure in first source; leukotriene receptor antagonist

tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity.
acetophenones;
aromatic ether;
phenols;
tetrazoles
anti-asthmatic drug;
leukotriene antagonist
vitamin k 3Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.1,4-naphthoquinones;
vitamin K
angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
raloxifeneraloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.1-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
1,6-bis(cyclohexyloximinocarbonyl)hexane1,6-bis(cyclohexyloximinocarbonyl)hexane: selective inhibitor of canine platelet diglyceride lipasecarbamate ester;
organonitrogen compound
vorinostatvorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
dicarboxylic acid diamide;
hydroxamic acid
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
5,5-dimethylhydantoin5,5-dimethylhydantoin: RN given refers to parent cpdimidazolidine-2,4-dione
benzenesulfonamidesulfonamide
plumbaginplumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.

plumbagin: a superoxide anion generator
hydroxy-1,4-naphthoquinone;
phenols
anticoagulant;
antineoplastic agent;
immunological adjuvant;
metabolite
wy 48252Wy 48252: leukotriene D4 antagonist
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenolstilbenoid
spiroglumidespiroglumide: a CCK receptor antagonist; antigastrin; structure given in first source
tamoxifenstilbenoid;
tertiary amino compound
angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
orlistatorlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.

Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.
beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative
anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
arachidonyltrifluoromethaneAACOCF3 : A fatty acid derivative that is arachidonic acid in which the OH part of the carboxy group has been replaced by a trifluoromethyl group

arachidonyltrifluoromethane: structure given in first source; inhibits 85-kDa phospholipase A2
fatty acid derivative;
ketone;
olefinic compound;
organofluorine compound
EC 3.1.1.4 (phospholipase A2) inhibitor
manoalidemanoalide : A sesterterpenoid isolated from the marine sponge Luffariella variabilis and which has been shown to exhibit inhibitory activity towards phospholipase A2.

manoalide: phospholipase A2 inhibitor; sesterterpene from marine sponge L. variabilis; structure given in first source
butenolide;
lactol;
sesterterpenoid
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
metabolite
darapladibdarapladib: a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk
sb-435495SB-435495: structure in first source
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene: has antineoplastic activity; also inhibits Fms-like tyrosine kinase-3; structure in first source